MapLight to discuss autism drug's future with FDA after Phase 2 miss
MapLight Therapeutics is holding to hope that there's a path forward for its autism drug despite the program flunking a mid-stage study. The biotech’s treatment...
MapLight Therapeutics is holding to hope that there's a path forward for its autism drug despite the program flunking a mid-stage study. The biotech’s treatment, known as ML-004, didn't meet the Phase 2 trial’s primary ...